Latest news with #Kerecis
Business Upturn
5 hours ago
- Business
- Business Upturn
Coloplast A/S – Interim Financial Report, 9M 2024/25
By GlobeNewswire Published on August 19, 2025, 10:33 IST 2024/25 Interim financial results, 9M 2024/25 1 October 2024 – 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from currencies and the Skin Care divestment. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%. Growth in Ostomy Care was driven by broad-based contribution across regions, except for China which delivered low-single digit growth, as expected. Growth in Continence Care was driven by continued strong contribution from the Luja™ portfolio. Voice and Respiratory Care growth was driven by continued good momentum in both Laryngectomy and Tracheostomy. Growth in Advanced Wound Dressings was -2%, driven primarily by a significant decline in China which was impacted by a preventative and voluntary product return of all Biatain® Adhesive foam dressings in the market. The product return is expected to have a negative revenue impact of around DKK 80 million in H2, of which around DKK 20 million impacted Q3. Kerecis grew 17%, with a 13% EBIT margin before PPA amortisation. Growth in the quarter was impacted by a slowdown in the out-patient setting due to the LCD postponement in April, causing a temporary market shift to high-priced products. Growth momentum in Q4 is expected to improve, with a good start to the quarter in July. Growth in Interventional Urology was driven by good momentum in the US Men's Health business, partly offset by continued negative impact from the product recall in Bladder Health and Surgery of around DKK -10 million in Q3. EBIT 1 was DKK 1,915 million, a 2% increase from last year. The EBIT margin 1,2 was 28%, against 27% last year. was DKK 1,915 million, a 2% increase from last year. The EBIT margin was 28%, against 27% last year. Changes to the Executive Leadership Team announced, to support the successful execution of the new company strategy towards 2030. 9M 2024/25 organic growth of 7% and EBIT margin1 of 27%. Reported revenue in DKK grew 4% to DKK 20,914 million. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 9% and Interventional Urology 1%. EBIT 1 was DKK 5,718 million, a 4% increase from last year. The EBIT margin 1 was 27%, on par with last year 2 . was DKK 5,718 million, a 4% increase from last year. The EBIT margin was 27%, on par with last year . Adjusted3 net profit before special items was DKK 3,778 million, a DKK 15 million decrease from last year, negatively impacted by non-cash effect from net financial expenses. Adjusted3 diluted earnings per share (EPS) before special items decreased by 1% to DKK 16.76. Adjusted3 ROIC after tax before special items was 15%, on par with last year. FY 2024/25 guidance is unchanged with organic growth of around 7% and an EBIT margin before special items of 27-28%. Organic growth now includes the negative impact from the product return in Advanced Wound Dressings in China, partly offset by good momentum in the other business areas. Reported growth in DKK is now expected to be 3-4%, with around 2%-points negative impact from currencies and around 1.5%-points negative impact from the Skin Care divestment. The assumptions on the reported EBIT margin before special items are largely unchanged. Special items expectations are unchanged, around DKK 450 million. Expectations on capital expenditures and tax rate (ordinary and effective) are also unchanged. 'We deliver a third quarter as expected with 7% organic growth and an EBIT margin of 28%, maintaining our financial guidance for 2024/25. Our Q3 performance was driven by broad-based growth across our chronic care businesses, offsetting the challenges in China. I'm pleased to see the global Coloplast organisation continuing to deliver on our priorities and moving the business forward. The search for Coloplast's new CEO remains on track. I look forward to presenting our 2030 strategy at our Capital Markets Day on 2 September alongside the new Executive Leadership Team, announced today,' says interim CEO Lars Rasmussen. 1. before special items expenses of DKK 83 million in Q3 2024/25 and DKK 241 million in 9M 2024/25. 2. before special items expenses of DKK 36 million in Q3 2023/24 and DKK 70 million in 9M 2023/24. 3. Adjusted for the impact from the Kerecis IP transfer. Conference call Coloplast will host a conference call on Tuesday, 19 August 2025 at 11.00 CEST. The call is expected to last about one actively participate in the Q&A session please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Register here Access the conference call webcast directly here: Coloplast – 9M 2024/25 conference call For further information, please contact Investors and analysts Anders Lonning-SkovgaardExecutive Vice President, CFO Tel. +45 4911 1111 Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 1800 / +45 4911 2458 Email: [email protected] Kristine Husted MunkSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 3266 Email: [email protected] Simone Dyrby HelvindSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 2981 Email: [email protected] Press and media Peter MønsterSr. Media Relations ManagerTel. +45 4911 2623 Email: [email protected] Address Coloplast A/SHoltedam 1DK-3050 HumlebaekDenmark Company reg. (CVR) no. 69749917 Website This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and commitment. We were born from a nurse's wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound Care, Interventional Urology and Voice and Respiratory Care. The Coloplast logo is a registered trademark of Coloplast A/S. © 2025-08. All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark. Attachment 06_2025_9M_2024_25_Earnings_release Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Wire
23-07-2025
- Business
- Business Wire
Kerecis to Showcase Fish-Tissue Derived Tendon Protection Surgical Graft at APMA 2025
ARLINGTON, Va. & REYKJAVIK, Iceland--(BUSINESS WIRE)--Kerecis, the company pioneering the use of fish-tissue in cellular therapy and tissue regeneration, will debut its latest innovation, SurgiBind® Tendon Protect, at the American Podiatric Medical Association's (APMA) Annual Scientific Meeting in Grapevine, Texas, July 24-27, 2025. The new biologic graft is designed for tendon procedures where no significant tissue loss is present and will be spotlighted during educational and interactive sessions throughout the conference. 'SurgiBind® Tendon Protect was developed in response to a need consistently identified by surgeons. Namely, coverage for repaired tendons that is straightforward to use and compatible with surgical workflows,' said Fertram Sigurjonsson, Founder and CEO of Share APMA 2025 As part of its presence at APMA 2025, Kerecis will exhibit at Booth #805 and host a clinical education event, 'Taste of Iceland,' on Friday, July 25, from 7:00 to 9:00 PM at Mission Plaza, Gaylord Texan Resort. During the session, Dr. James Cottom, DPM, will present 'Gliding into Enhanced Tendon Outcomes with Intact Fish Skin,' a talk exploring the clinical use of SurgiBind® Tendon Protect in tendon repair procedures. Attendees will also have the opportunity to learn more about the broader application of intact fish-tissue grafts while sampling traditional Icelandic cuisine. Designed for Tendon Protection and Surgical Efficiency Each year, an estimated 500,000 tendon procedures are performed in the United States, many of which aim to preserve or restore movement following tendon injury. SurgiBind® Tendon Protect is intended to be wrapped around a repaired tendon during surgery and is cleared for implantation to reinforce soft tissue where weakness exists. The product is a solid, intact fish-tissue based graft, sustainably sourced from North Atlantic cod, and is bioresorbable, non-crosslinked, and designed to be sutured and positioned with ease in the surgical field. 'Tendon Protect was developed in response to a need consistently identified by surgeons. Namely, coverage for repaired tendons that is straightforward to use and compatible with surgical workflows,' said Fertram Sigurjonsson, Founder and CEO of Kerecis. 'The result is a graft that is structurally sound and easy to handle, offering an alternative to mammalian-derived products.' Clinical Use SurgiBind® Tendon Protect is intended for use in ambulatory surgical centers (ASCs) and hospital outpatient departments (HOPDs), providing a physical covering around repaired tendons where there is no significant tissue loss. Its strength and pliability support secure placement and suture fixation and reduces the risk of readmissions or revision procedures related to scarring or adhesion, factors that can increase overall treatment costs and affect reimbursement. Audit-Ready™ To support providers, Kerecis offers coding and reimbursement guidance through its Audit-Ready™ program, designed to align with U.S. payor requirements, reduce administrative burden, and streamline claims and documentation. Available Nationwide SurgiBind® Tendon Protect marks the continued expansion of the Kerecis SurgiBind® portfolio, which now includes options for general surgical, trauma, and tendon-related procedures. The product is currently available across the United States through Kerecis' direct sales force. About Kerecis Kerecis, founded by Fertram Sigurjonsson, develops intact fish tissue derived products for cellular therapy, tissue regeneration, and protection. When grafted onto damaged human tissue or implanted, the patented material supports the body's own processes to heal and regenerate. Because no disease-transfer risk exists between cold-water fish and humans, Kerecis products are only gently processed and retain their similarity to human tissue. The gentle processing preserves the material's original three-dimensional structure, maintaining its inherent natural strength, complexity, and molecules (such as fatty acids). Clinical studies show that Kerecis products heal wounds faster than competitors. Kerecis is the only global manufacturer of medical devices containing intact fish-tissue and is the fastest growing company in the U.S. xenograft biologics skin market. Products include SurgiBind®/SurgiClose®, GraftGuide®, MariGen®, and Shield™ for various medical applications. Committed to the UN Sustainable Development Goals, Kerecis uses sustainably sourced Icelandic fish processed with renewable energy. Kerecis is a part of Coloplast, a leading supplier of intimate healthcare products. For more information about Kerecis and its clinical research, visit Trademarks and registered trademarks are the property of their respective owners.
Business Wire
17-07-2025
- Business
- Business Wire
Medical-Fish-Skin Company Kerecis Receives the Premier Sustainability Award for Reducing Greenhouse Gas Emissions
ARLINGTON, Va. & REYKJAVIK, Iceland--(BUSINESS WIRE)--Kerecis, the company pioneering the use of sustainably sourced fish skin and fatty acids in cellular therapy and tissue regeneration, received Premier's Sustainability Award for Reducing Greenhouse Gas Emissions this week. Members of Premier, the second-largest group purchasing organization in the U.S., selected Kerecis for the prestigious award in recognition of its leading sustainability practices and waste-to-value innovation. 'Sustainability is not a secondary initiative for Kerecis, it's foundational to our business model,' said Fertram Sigurjonsson, Founder and CEO of Kerecis. Share Using 100% renewable energy to power its manufacturing facilities, Kerecis converts cod fish skin, a material traditionally discarded as waste, to high-value medical technology that heals. As part of its operating model, Kerecis leverages electric vehicles for transportation, centralizes distribution for efficiency, and reduces product waste with recycled packaging. Drawing on its greenhouse gas emissions audits (based on ISAE 3000 standards), the company proved that it outperforms its competitors in the medical device industry with significantly lower CO2 emissions. For example, Kerecis' CO 2 emissions per $1,000 of gross revenue are just 0.02 tons (compared to an average of 0.19 tons among competitors). And its CO 2 emissions per full-time employee are just 5 tons (compared to an average of 57.5 tons among competitors). Moving forward, Kerecis will continue to measure its greenhouse gas emissions to minimize its environmental impact, applying the same rigorous data-driven approaches that it uses to measure its medical product efficacy and patient outcomes. Accepting the Sustainability Award at Premier's Breakthroughs 25 Conference in National Harbor, Kerecis' Founder and CEO Fertram Sigurjonsson reaffirmed Kerecis' commitment to reducing its carbon footprint and to delivering sustainably sourced, life-saving products. 'Sustainability is not a secondary initiative for Kerecis, it's foundational to our business model,' said Fertram Sigurjonsson, Founder and CEO of Kerecis. 'We are thrilled to be recognized by Premier for our commitment to responsible manufacturing and for showing that environmental and clinical priorities can align. This award reinforces our approach to building value from resources that would otherwise go to waste.' About Kerecis Kerecis, founded by Fertram Sigurjonsson, develops intact fish skin products for cellular therapy, tissue regeneration, and protection. When grafted onto damaged human tissue or implanted, the patented material supports the body's own processes to heal and regenerate. Because no disease-transfer risk exists between cold-water fish and humans, the Kerecis fish-skin is only gently processed and retains its similarity to human tissue. The gentle processing preserves the skin's original three-dimensional structure, maintaining its inherent natural strength, complexity, and molecules (such as fatty acids). Clinical studies show that Kerecis products heal wounds faster than competitors. Kerecis is the only global manufacturer of medical devices containing intact fish-skin and is the fastest growing company in the U.S. biologics skin market. Products include SurgiBind®/SurgiClose®, GraftGuide®, MariGen®, and Shield™ for various medical applications. Committed to the UN Sustainable Development Goals, Kerecis uses sustainably sourced Icelandic fish processed with renewable energy. Kerecis is a part of Coloplast, a leading supplier of intimate healthcare products. For more information about Kerecis and its clinical research, visit Trademarks and registered trademarks are the property of their respective owners.
USA Today
05-07-2025
- Health
- USA Today
Injured bald eagle, healed with fish skin, released back into the wild
Veterinarians saved the raptor from a devastating leg injury using a pioneering fish skin treatment. They released her back to freedom days before Independence Day. A badly injured bald eagle saved by a pioneering fish skin treatment is back in the wild, just in time for the Fourth of July. The bird, named Kere, was on the verge of death when volunteers brought her to the Winged Freedom Raptor Hospital in northern Wisconsin last August. Her leg was ripped open from knee to ankle, and maggots and bacteria had begun to fill the dried-out wound. 'It was horrendous,' said Veterinarian Kim Ammann. But the doctor saw a flicker of hope: the eagle was somehow standing on the bandaged-up leg, and its talons still worked. 'That's when I started to figure I was going to need something to close the wound,' said Ammann A few Google searches later, Ammann stumbled on the Icelandic company Kerecis, which transplants the skin of North Atlantic cod to help heal human wounds and support tissue regeneration. The treatment had never been used on a species of raptor before, but Ammann took a leap and sent them an email. Almost 'immediately,' she said the company reached back out and offered the descaled, medical fish skin free of charge to the all-volunteer veterinary hospital. Within weeks, Ammann gave Kere, who is named in honor of the company, the first of two successful surgical skin grafts. The rest of her recovery included about 10 months of grueling wound care, bandage changes, and a mini vacation in the hospital's Eagle flyway rehabilitation enclosure. 'There was something very special about the fact that she was an eagle and that she was allowing me to do this,' Ammann said of the bird. 'That tolerance was part of what made it possible.' By June 22, the wild bald eagle was ready to soar free again. The date was more about ensuring Kere had 'the majority of the summer months' to reacclimate with being wild again. But the symbolism of releasing a bald eagle so close to the Fourth of July wasn't lost on Ammann A group of about a hundred viewers gathered to watch Kere take flight above the forests and fields. Amann described the day as 'magical.' 'She could decide whether she wanted to go east or west. She could decide what lake she wanted to go to,' Ammann said. 'I was so happy for her to have her independence back.' A conservation success story Bald eagles, an iconic symbol of the United States, are among the most protected species in the country. But they haven't always been. The bird's population began plummeting in the late 1800s as American industrialization began changing the landscape, destroying their habitats and introducing lead into the environment. In 1940, the federal government enacted The Bald and Golden Eagle Protection Act prohibiting people from hunting, selling or possessing an eagle ‒ in effort to prevent further population decline. But decades later, pesticides, including DDT, seeped into waterways and further endangered the species. The chemicals were believed to thin bald eagle eggs, decreasing the bird's reproductive success. The bald eagle population hit an all-time low in the 1960s, with just 417 nesting pairs in the continental U.S, according to the Smithsonian's National Zoo and Conservation Biology Institute. The United States banned DDT in 1972 and passed The Endangered Species Act in 1973, to protect quickly disappearing species like the bald eagle. The raptor was taken off the endangered species list in 2007 as conservation efforts led to a population surge. Today, there are an estimated 316,000 bald eagles in the lower 48 states. And in 2024, they became the country's national bird .
The Guardian
02-07-2025
- Health
- The Guardian
US vet uses cod skin to save bald eagle in time for Fourth of July
A veterinarian saved the life of a badly injured American bald eagle using a pioneering fish skin graft procedure more commonly used for human wound, releasing the bird back into the wild in a symbolic act ahead of the Fourth of July holiday. The adult raptor named Kere was found by a park visitor in Hayward, Wisconsin, in August, with one of its legs ripped open from knee to ankle from an unknown injury, and appearing severely underweight. With a deep infection already set in, and no healthy skin to work with, Dr Kimberly Ammann, founder and chief vet of the Winged Freedom Raptor Hospital in Spooner, said she initially figured euthanasia was the only option. But the bird's claws were still functioning, and Ammann remembered learning about the potential of skin graft procedures from her veterinary training. 'I thought if I could get it to heal she could survive, because her toes worked, her foot worked,' she said. A Google search led her to Kerecis, an Iceland-based company that has advanced the use of Atlantic cod skin for grafts on humans with advanced or challenging wounds, but which had never previously been asked to help with a bird of prey. Kerecis sent over sterilised, dehydrated and descaled fish skin patches, and with the assistance of technical advice from the company, Ammann set to work repairing the eagle's leg. She said the patch took well, and with follow-up procedures to add fragmented fish skin to fill gaps and promote tissue regeneration, Kere – who was named by Amman and her staff to honor the company's support – improved quickly through a 10-month rehabilitation period. 'The only reason this worked is because she was such a good patient,' said Ammann, who treated 75 injured or sick bald eagles at her hospital last year. 'She insisted on watching everything I did. I could not put a hood or a towel over her. Her wings were restrained but she never resisted and was so tolerant of all the time it took. She was stuck in an indoor room to keep it clean, no water, no bath and we had to keep a bandage on the whole time. She was amazing.' Ammann said it was an emotional day when Kere was finally released on 22 June, but that she cried more during the final examination when she determined the eagle's wound was sufficiently healed. 'I laid her down to get a last picture, and I realized I was never going to touch this bird again, I would never have my hands on her again, and that got me,' she said. 'Even though I'm their doctor, and you keep all that objectivity and everything, I do get emotionally attached to these birds, every single one of them, and this one was very special.' Kere's release, watched by about a hundred people, including hospital staff, volunteers and workers from the Wisconsin department of natural resources, came amid preparations for the independence day holiday, which to Ammann was fitting given the bald eagle's significance as a symbol of American liberty. 'I'm so excited for her,' she said. 'She can choose where she wants to go, what lake she wants to sit on, where she's going to fish. She has all the freedom to make those choices now, and what better time to be able to do that than the Fourth of July?'
